Links to IMI SUMMIT project

SUMMIT (Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools) is a pan-European research consortium funded by the Innovative Medicines Initiative (IMI).

The IMI SUMMIT project aims to systematically idenitfy genetic risk factors for chronic diabetic complications and therefore strongly links to the work carried out by the CEED3 consortium in work package 5. This work package is focused on the validation and clinical application in the identification of subjects with early development of vascular complications.

Four of the CEED3 partners are involved in the SUMMIT project which brings together the scientific expertise and clinical resources from 19 leading universities and research institutes, six pharmaceutical companies and one small/medium sized entreprise (SME). The project started 11 months after CEED3 on November 1, 2009 and will last for five years

More information about the SUMMIT project can be found here